<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788108</url>
  </required_header>
  <id_info>
    <org_study_id>177/2021</org_study_id>
    <nct_id>NCT04788108</nct_id>
  </id_info>
  <brief_title>Oral Progesterone for Prevention of Miscarriage in Threatened Abortion</brief_title>
  <official_title>Oral Progesterone for Prevention of Miscarriage in Threatened Abortion: a Randomized, Double-blinded, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in&#xD;
      threatened abortion. Half of participants will receive oral dydrogesterone, while the other&#xD;
      half will receive oral placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>continue pregnancy more than 20 weeks gestation</measure>
    <time_frame>at 20 weeks gestation</time_frame>
    <description>percentage of cases with continue pregnancy more than 20 weeks gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>preterm delivery less than 34 weeks</measure>
    <time_frame>at 34 weeks gestation</time_frame>
    <description>percentage of delivery less than 34 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preterm delivery less than 37 weeks</measure>
    <time_frame>at 37 weeks gestation</time_frame>
    <description>percentage of delivery less than 37 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>placenta previa</measure>
    <time_frame>31 weeks</time_frame>
    <description>percentage of placenta previa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abruptio placenta</measure>
    <time_frame>31 weeks</time_frame>
    <description>percentage of abruptio placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine growth restriction</measure>
    <time_frame>31 weeks</time_frame>
    <description>percentage of intrauterine growth restriction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal complications</measure>
    <time_frame>31 weeks</time_frame>
    <description>percentage of newborn with respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>percentage of side effects such as headache, nausea/vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance</measure>
    <time_frame>6 weeks</time_frame>
    <description>percentage of complete drug use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal satisfaction</measure>
    <time_frame>6 weeks</time_frame>
    <description>percentage of good satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time until bleeding stops</measure>
    <time_frame>6 weeks</time_frame>
    <description>time from first bleeding until bleeding stops</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Threatened Abortion</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dydrogesterone 10 mg by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo by mouth every 12 hours until 1 week after bleeding stops or until 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <description>Dydrogesterone tablet</description>
    <arm_group_label>Dydrogesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  singleton pregnancy with gestational age 6 - 20 weeks&#xD;
&#xD;
          -  threatened abortion&#xD;
&#xD;
          -  confirmed intrauterine pregnancy with a viable fetus by ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of recurrent miscarriage&#xD;
&#xD;
          -  having endocervical polyp&#xD;
&#xD;
          -  having infection such as pneumonia, pyelonephritis, septicemia&#xD;
&#xD;
          -  having autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis,&#xD;
             rheumatoid arthritis&#xD;
&#xD;
          -  having cancer&#xD;
&#xD;
          -  having coagulation defect&#xD;
&#xD;
          -  allergy to dydrogesterone&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vorapong Phupong, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chulalongkorn University, Faculty of Medicine, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vorapong Phupong, M.D.</last_name>
    <phone>+6626492115</phone>
    <email>vorapong.p@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arissara Kuptarak, M.D.</last_name>
    <phone>+6626492115</phone>
    <email>arissaramd@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018 Nov;132(5):e197-e207. doi: 10.1097/AOG.0000000000002899.</citation>
    <PMID>30157093</PMID>
  </reference>
  <reference>
    <citation>Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016;32(2):97-106. doi: 10.3109/09513590.2015.1121982. Epub 2016 Jan 22. Review.</citation>
    <PMID>26800266</PMID>
  </reference>
  <reference>
    <citation>Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16. Review.</citation>
    <PMID>14670641</PMID>
  </reference>
  <results_reference>
    <citation>Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol. 2005 Dec;97(5):421-5. Epub 2005 Nov 15.</citation>
    <PMID>16293412</PMID>
  </results_reference>
  <results_reference>
    <citation>Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009 Dec;65 Suppl 1:S47-50. doi: 10.1016/j.maturitas.2009.11.016. Epub 2009 Dec 14.</citation>
    <PMID>20005647</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009 Dec;65 Suppl 1:S43-6. doi: 10.1016/j.maturitas.2009.11.013. Epub 2009 Dec 14.</citation>
    <PMID>20007011</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Vorapong Phupong</investigator_full_name>
    <investigator_title>Head of Placental Related Diseases Research Unit, Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <keyword>threatened abortion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Threatened</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

